• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Cytox Collaborates with Mayo Clinic to Develop New Algorithms to Evaluate Genetic Based Approaches for Assessing Alzheimer’s Risk

by Fred Pennic 05/23/2018 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Alzheimer's Clinical Trials Consortium

Cytox, a precision medicine company focused on commercializing polygenic risk scoring (PRS) approaches for assessing genetic risk for developing Alzheimer’s has entered into a research collaboration with Mayo Clinic to test current and develop new proprietary algorithms relating to the diagnosis and prognosis of Alzheimer’s disease. 

Under the agreement Cytox will assess genetic risk for developing Alzheimer’s disease using its current commercially available approaches developed to run on the Thermo Fisher Scientific Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrument platform, in addition to new approaches under development. Mayo Clinic’s Alzheimer’s Disease Research Center will provide biobank samples from research participants classified as clinically normal, diagnosed with mild cognitive impairment and diagnosed with mild Alzheimer’s disease with associated amyloid PET imaging data. Genotyping of DNA samples will be performed by Cytox’s US genotyping services partner, AKESOgen, an integrated genomics, genetics and biobanking company and precision medicine leader based near Atlanta, Georgia.

“The Mayo Clinic Alzheimer’s biobank presents a tremendous research opportunity, not only due to the thousands of blood samples it holds, but also because of the clinical annotation accompanying the samples,” commented Dr Richard Pither, CEO of Cytox, “By working closely with Mayo Clinic and its researchers, we hope to further validate the performance of our current approaches for assessing genetic risk for developing Alzheimer’s disease, and develop new, more targeted, precision-based methods. We hope that data generated through this collaboration will enable the identification of a predictive polygenic risk score that then can be applied to other cohorts for future studies, such as clinical trials, that could benefit from stratification based on the risk of developing disease. Over time we plan to make the products and services that result from this collaboration available to both physicians and patients.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Alzheimer’s disease, Cytox, dementia, genomic precision medicine, Mayo Clinic, polygenic risk scoring (PRS)

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

 How Top Health Plans Use AI to Save Money and Work Smarter How Top Health Plans Use AI to Save Money and Work Smarter

 How to Build Hybrid Care Models Around Remote Patient Monitoring How to Build Hybrid Care Models Around Remote Patient Monitoring

Trending

Consumers Believe Generative AI Can Revolutionize Healthcare

71% of Consumers Believe Generative AI Can Revolutionize Healthcare

NCQA Launches Virtual Care Accreditation Pilot

NCQA Launches Virtual Care Accreditation Pilot

Novant Health Acquires Three Tenet Hospitals in South Carolina for $2.4 Billion

M&A: Novant Health Acquires 3 Tenet Hospitals in South Carolina for $2.4B

UnitedHealthcare Launches Virtual Prescription Renewal Option

UnitedHealthcare Accused of Using Faulty AI Model to Deny Healthcare Claims to Elderly Patients

Meet The Circular Smart Ring Slim, The Slimmest and Lightest Smart Ring in the World

Meet The Circular Smart Ring Slim, The Slimmest and Lightest Smart Ring in the World

MIT Spun Out Layer Health Launches with $4M to Build the AI Layer for Healthcare

MIT Spun Out Layer Health Launches with $4M to Build the AI Layer for Healthcare

Edge Computing's Role in Shaping the Future of Wearable Healthcare

Edge Computing’s Role in Shaping the Future of Wearable Healthcare

In-Ear Wearable Measures Blood Flow to the Head for Long COVID, POTS

In-Ear Wearable Measures Blood Flow to the Head for Long COVID POTS

NYU Langone Health Makes History with Successful Whole-Eye & Partial-Face Transplant

NYU Langone Health Makes History with Successful Whole-Eye & Partial-Face Transplant

Better Data for Better Health Among Medicaid Recipients

Better Data for Better Health Among Medicaid Recipients

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |